Applying Lucentis for the treatment of retinopathy of prematurity by S. V. Lesovoy, O. A. Boginskaya

“…Purpose: to evaluate the efficacy of Lucentis for the treatment of retinopathy of prematurity (ROP). …”
Get full text

Looking beyond Lucentis on the management of macular degeneration. by Fletcher, E, Chong, N

On the efficiency of treatment of wet age-related macular degeneration with Lucentis by E. M. Kasimov, A. M. Shakhmaliyeva, B. H. Gadzhiyeva

“…The paper studies the efficiency of ranibizumab (Lucentis, Novartis Pharma), a VEGF blocker inhibiting angiogenesis, in patients with wet age macular degeneration (AMD) at different stages of the pathological process. …”
Get full text

Formulation and in-vitro release studies of Ranibizumab (Lucentis) loaded liposomes by Ang, Jin Yan

“…Physical Characterization of Lucentis was carried out with the effect of incubation of Lucentis under temperature and Triton X-100. …”
Get full text

A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment by Marko Andric, Shreya Dixit, Dana Robaei, Rosemary Watchorn, Nitin Verma

“…Following a single intraocular injection of Lucentis (ranibizumab), she developed a subacute cutaneous lupus erythematosus which, with treatment, took nearly 12 months to resolve. …”
Get full text

INTRAVITREAL INTRODUCTION OF LUCENTIS AND TRANS-SCLERAL CYCLOPHOTOCOAGULATION IN THE TREATMENT OF NEOVASCULAR GLAUCOMA IN DIABETES MELLITUS by V. P. Fokin, S. V. Balalin, T. G. Yefremova, V. N. Potapova

“…During the year period, the second stage (intravitreal introduction of Lucentis) was performed in all patients. As a result, IOP was reduced to 17.5 ± 0.09 mmHg. …”
Get full text

Comparison of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by Optical Coherence Tomography by Hossam El din Khalil, Abdel Rahman Ahmed, Hassan Mahfouz Eliwa

“…Objective: To compare the effect of Aflibercept (Eylea®) with Ranibizumab (Lucentis®) in treatment of diabetic macular edema by OCT. …”
Get full text

Comparative study of inhibition effects of Avastin and Lucentis on human umbilical vein endothelial cell proliferation and migration by Xin Jin, Bing Chen, Tie-Cheng Liu, Mao-Nian Zhang

Subjects: Get full text

Efficacy of intravitreal injection of Lucentis in the treatment of diffuse diabetic macular edema associated with pan-retinal photocoagulation in proliferative diabetic retinopathy by L. N. Boriskina, M. Y. Guro, V. N. Potapova, I. A. Melichova, V. R. Polyakova

Subjects: “…intravitreal injection of lucentis…”
Get full text

Comparison between the Effect of Aflibercept (Eylea) and Ranibizumab (Lucentis) on Intraocular Pressure after 3rd Injection in Treatment of Diabetic Macular Edema by Hossam El Deen Khalil, Ahmed Gouda, Ibrahim Abd Allah

Subjects: Get full text

Intravitreal injection of ranibizumab (Lucentis) versus pan-retinal photocoagulation as a preoperative adjuvant before vitrectomy in management of proliferative diabetic retinopathy by Mohammed S Ahmed

“…Aim This study was conducted to study the effect of intravitreal injection of ranibizumab 10 mg/ml (Lucentis) versus PRP as an adjuvant before vitrectomy in the management of PDR. …”
Get full text

Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration by Peter K. Kaiser, Jihoon Yun, Soyeon Kim, Jihyun Kim, Su Jin Park

Subjects: Get full text

EXPERIENCE OF SURGICAL TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY by O. M. Trubina, V. N. Kanyukov, A. N. Kazennov, I. A. Kazennova

Subjects: Get full text

A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis® in patients with neovascular age-related macular degeneration by Ramandeep Singh, Rohan Chauhan, Ashish Saxena, Anup Shah, Laxshmi Mondal, Dhananjay Bakhle, Chirag Shah, Arpit Shah, Shashank Deoghare, Neelakant Krishnan, Neelima Godse

Subjects: Get full text

Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients by Zhe-Li Liu, Feng Gu, Peng Sun, Han Zhang, Jun Li

Subjects: Get full text

Response to commentary on: A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's ranibizumab with Lucentis in patients with neovascular age-related macular degeneration by Chirag Shah, Kishore Sonkusare

Get full text

Recurrence of Macular Hole Retinal Detachment after Intravitreal Ranibizumab Injection for the Treatment of Choroidal Neovascularization from the Remaining Macular Hole Edge by Keiko Otsuka, Hisanori Imai, Tsuyoshi Shimoyama, Takayuki Nagai, Shigeru Honda, Atsushi Azumi

Subjects: Get full text

Assessment of Anti-VEGFs in Treating Diabetic Macular Edema in Alfaisal Eye Center, Khartoum, Sudan, 2019 by Ahmedalgabri RHM, Omer T, Zarroug F, Elkhawad AO, Noma M

“…The mean BCVA before and after treatment for both drugs respectively 0.19 min and 0.21 min was statistically correlated (p = 0.000). For patients under Lucentis, the mean BCVA before and after medication was 0.20 min– 0.24 min and 0.19– 0.19 min for those who used Avastin. …”
Get full text

Studies on sustained release platforms for delivery of therapeutic agents to the posterior segment of the eye by Joseph, Rini Rachel

“…Trans-scleral transport of Lucentis from different liposome-encapsulated formulations was compared with trans-scleral transport of bare-Lucentis and found to be slowed down in the case of encapsulated formulations. …”
Get full text

Study on ocular drug delivery system for treatment of posterior segment eye diseases by Tan, Sharon Kai Ling

“…ELISA and microBCA tests were carried out and results proved that degradation of Lucentis occurred over the 10 weeks of incubation. …”
Get full text